SCHEMBL351763

SCHEMBL351763

C=CCN1CCC[C@H]1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
ACE P12821 7/20 0.40
CYP2C19 P33261 2/20 0.40
REN P00797 3/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
F2 P00734 1/20 0.38
LTA4H P09960 1/20 0.38
MAPT P10636 1/20 0.38
PEPD P12955 1/20 0.38
ALOX15 P16050 1/20 0.38
PTGS1 P23219 1/20 0.38
HTR2A P28223 1/20 0.38
PTGS2 P35354 1/20 0.38
HRH1 P35367 1/20 0.38
THPO P40225 1/20 0.38
PMP22 Q01453 1/20 0.38
ACE2 Q9BYF1 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL351762 1.00 CYP1A2 (0.40) CYP1A2ACECYP2C19RENLMNA
SCHEMBL15665285 1.00 CYP1A2 (0.40) CYP1A2ACECYP2C19RENLMNA
Hydrochloric Acid SCHEMBL9734098 0.98 CYP1A2 (0.40) CYP1A2ACECYP2C19RENLMNA
Hydrochloric Acid SCHEMBL19510378 0.98 CYP1A2 (0.40) CYP1A2ACECYP2C19RENLMNA
SCHEMBL31053890 0.98 CYP1A2 (0.40) CYP1A2ACECYP2C19RENLMNA
SCHEMBL5531122 0.95 SMN1; SMN2 (0.43) CYP1A2ACECYP2C19SMN1; SMN2
SCHEMBL5898651 0.93 SMN1; SMN2 (0.42) CYP1A2ACECYP2C19SMN1; SMN2
SCHEMBL5898685 0.89 ACE (0.37) ACE
SCHEMBL5701867 0.89 ACE (0.37) ACE
SCHEMBL5701885 0.89 ACE (0.37) ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112174870-A Preparation method and medicinal application of (R) -1-alkanoyl-2-substituted pyrrolidine-2-formamide 蔡霈 2021-01-05 CN claimed
EP-3239123-B1 METHOD OF PREPARING DIFLUORINATED ALCOHOL COMPOUND SAMHWA PAINTS IND CO LTD (KR) 2020-01-29 EP claimed
US-10329341-B2 Collagen mimics WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2019-06-25 US claimed
US-20180030115-A1 COLLAGEN MIMICS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-02-01 US claimed
EP-2760881-B1 NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS NOSOPHARM (FR) 2017-11-01 EP claimed
US-9758569-B2 Collagen mimics WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2017-09-12 US claimed
US-9260481-B2 Peptide derivatives as antibiotics NOSOPHARM (FR) 2016-02-16 US claimed
US-20150353619-A1 Non-Canonical Insulins and Their Uses CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-12-10 US claimed
US-20150175659-A1 Peptide Derivatives as Antibiotics INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2015-06-25 US claimed
EP-2760881-A1 NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS Nosopharm (FR) 2014-08-06 EP claimed
WO-2013045600-A1 NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS NOSOPHARM (FR) 2013-04-04 WO claimed
US-20100016545-A1 PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) 2010-01-21 US claimed
WO-2007139914-A2 COLLAGEN MIMICS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-12-06 WO claimed
US-20070275897-A1 Collagen mimics NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-11-29 US claimed
US-20060136023-A1 Method and apparatus for patient temperature control employing administration of anti-shivering agents MARVIN, ROBERT 2006-06-22 US claimed
US-6869440-B2 Method and apparatus for patient temperature control employing administration of anti-shivering agents INNERCOOL THERAPIES, INC. (US) 2005-03-22 US claimed
US-20030060863-A1 Method and apparatus for patient temperature control employing administration of anti-shivering agents ZOLL CIRCULATION, INC. 2003-03-27 US claimed
WO-2003015672-A1 METHOD AND APPARATUS FOR PATIENT TEMPERATURE CONTROL EMPLOYING ADMINISTRATION OF ANTI-SHIVERING INNERCOOL THERAPIES, INC. (US) 2003-02-27 WO claimed
CN-122055379-A Compounds containing one or more diboronate esters and related insulin analogues 普罗托莫科技公司 2026-05-15 CN disclosed
US-4284624-A HYPOTENSIVE PEPTIDES E. R. SQUIBB & SONS, INC. (US) 1981-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016545-A1 PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT CX3CR1, NR3C2, NR4A2 CYP1A2 917/4885ACE 4286/4885CYP2C19 3510/4885
US-20150353619-A1 Non-Canonical Insulins and Their Uses IAPP, IDE, INSR CYP1A2 2895/4885ACE 164/4885CYP2C19 258/4885
US-20150175659-A1 Peptide Derivatives as Antibiotics VIP, NGLY1, NRDC CYP1A2 4521/4885ACE 70/4885CYP2C19 3537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.